Please assess the completion status of the following clinical trial:

Trial Title: Welchol as Monotherapy for Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects \>= 18 years of age;~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol.~* Diagnosis of Type 2 Diabetes Mellitus;~* HbA1C \>= 7.5% and =\< 9.5 % at screening;~* Fasting C-peptide \>0.5 ng/mL at screening;~* Drug naïve (no prior treatment with OAD) or having received no pharmacologic therapy for diabetes for the 3 month period prior to screening;~* Clinically stable in regards to medical conditions other than type 2 diabetes;~* Concomitant medications must be at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period; and~* Fasting glucose =\< 240 mg/dL at randomization~Exclusion Criteria:~* A history of type 1 diabetes and/or a history of ketoacidosis;~* History of bowel obstruction;~* History of hypertriglyceridemia-induced pancreatitis;~* Fasting serum triglyceride concentrations \>500 mg/dL;~* History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal (GI) motility disorders, or major GI surgery;~* History of insulin use of \>= 2 weeks duration in the previous 3 months or a total of \> 2 months of insulin therapy at any time prior to screening;~* Two or more fasting self-monitored blood glucose (SMBG) levels \>240 mg/dL during the placebo lead-in period.~* Previous treatment with a bile acid sequestrant, including Welchol within the 3 months prior to screening;~* Body mass index (BMI) \>40 kg/m2;~* Weight loss \> 3% in prior 3 months; and~* LDL \<60 mg/dL.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Welchol (Type: EXPERIMENTAL): Welchol 625mg tablets
- placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).